Degarelix as a new antiangiogenic agent for metastatic colon cancer?  

作　　者：Francois Ghiringhelli Nicolas Isambert Sylvain Ladoire 

机构地区：[1]Unite Mixte de Recherche 866,Institut National de la Sante et de la Recherche Medicale/Universite de Bourgogne,21000 Dijon,France [2]Departement of Oncologie Medicale,Centre Georges Francois Leclerc,21000 Dijon,France

出　　处：《World Journal of Gastroenterology》2013年第5期769-772,共4页世界胃肠病学杂志（英文版）

摘　　要：Recently,follicle stimulating hormone receptor was found to be selectively expressed by endothelial cells on tumor-associated blood vessels in a wide range of human cancers.In this context,we hypothesized that degarelix,a new gonadotropin-releasing hormone receptor antagonist developed for patients with prostate cancer,may have antiangiogenic effects via its capacity to block follicle stimulating hormone(FSH)production. We report the case of a patient with metastatic colon cancer exhibiting tumor progression after failure of all conventional chemotherapeutic regimens.The addition of degarelix to the last chemotherapeutic regimen was proposed as compassionate treatment.Degarelix induced a rapid decrease in FSH level.This treatment induced radiological stabilization and carcinoembryonic antigen stabilization during 1 year.Contrast-enhanced ultrasonography demonstrated reduction of tumor vas-clature.This case represents the first report of an antitumoral effect of degarelix in metastatic colon cancer and suggests an antiangiogenic property of this drug.Recently, follicle stimulating hormone receptor was found to be selectively expressed by endothelial cells on tumor-associated blood vessels in a wide range of human cancers. In this context, we hypothesized that degarelix, a new gonadotropin-releasing hormone receptor antagonist developed for patients with prostate cancer, may have antiangiogenic effects via its capacity to block follicle stimulating hormone (FSH) production. We report the case of a patient with metastatic colon cancer exhibiting tumor progression after failure of all conventional chemotherapeutic regimens. The addition of degarelix to the last chemotherapeutic regimen was proposed as compassionate treatment. Degarelix induced a rapid decrease in FSH level. This treatment induced radiological stabilization and carcinoembryonic antigen stabilization during 1 year. Contrast-enhanced ultrasonography demonstrated reduction of tumor vasclature. This case represents the first report of an antitumoral effect of degarelix in metastatic colon cancer and suggests an antiangiogenic property of this drug.

关 键 词：COLON cancer DEGARELIX CHEMOTHERAPY ANGIOGENESIS ANTIANGIOGENIC AGENTS 

分 类 号：R735.35[医药卫生—肿瘤]